Skip to main content
SpringerLink
Log in

Role of the IGF System in Breast Cancer Proliferation and Progression

  • Chapter
Endocrinology of Breast Cancer

Part of the book series: Contemporary Endocrinology ((COE,volume 11))

Abstract

The insulin-like growth factor (IGF) family consists of two ligands (IGF-I and IGF-II), three receptors (IGFR1, IGFR2, and hybrid IGFR1/insulin receptor) and seven IGF binding proteins (IGFBP1-7). Similar to many other growth factor families such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), the number and variety of effects that can be elicited by the IGF family are very diverse and continue to expand (1). In particular, the ability of different ligands, receptors, and binding proteins to crossreact and the ensuing variety of biologic effects make assigning specific roles for each member difficult. This is especially true for the IGFBPs; several years of research have still failed to elucidate the true function of these proteins in IGF action (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schofield PN (1992) The Insulin-Like Growth Factors. Oxford University Press, Oxford.

    Google Scholar 

  2. Clemmons DR, Busby WH, Arai T, Nam TJ, Clark JB, Jones JI, et al. (1995) Role of insulin-like growth factor binding proteins in the control of IGF action. Prog Growth Factor Res 6: 357–366.

    Article  PubMed  CAS  Google Scholar 

  3. Daughaday, W (1988) Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10: 68–91.

    Google Scholar 

  4. Baserga, R (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249–252.

    PubMed  CAS  Google Scholar 

  5. Baker J, Liu J-P, Robertson EJ, Efstratiadis, A (1993) Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73–82.

    PubMed  CAS  Google Scholar 

  6. Liu J-P, Baker J, Perkins AS, Robertson, E, Efstratiadis, A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (igflr). Cell 75: 59–72.

    PubMed  CAS  Google Scholar 

  7. Ullrich A, Gray A, Tam A, Yang-Feng T, Tsubokawa M, Collins C, et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503–2512.

    PubMed  CAS  Google Scholar 

  8. Moxham CP, Duronio, V, Jacobs, S (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264: 13238–13244.

    Google Scholar 

  9. Treadway JL, Fratalli AL, Pressin JE (1992) Intramolecular subunit interactions between insulin and insulin-like growth factor-1 aßH half-receptors induced by ligand and Mn/MgATP binding. Biochemistry 31: 11801–11805.

    Article  PubMed  CAS  Google Scholar 

  10. Soos MA, Field CE, Siddle, K (1993) Purified hybrid insulin/insulin-like growth factor I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290: 419–426.

    PubMed  CAS  Google Scholar 

  11. Steele-Perkins G, Turner J, Edman J, Hari J, Pierce S, Stover C, et al. (1988) Expression and characterisation of a functional human insulin-like growth factor I receptor. J Biol Chem 23: 11486–11492.

    Google Scholar 

  12. Morgan DO (1987) Insulin-like growth factor II receptor as a multi-functional binding protein. Nature 326: 300–307.

    Google Scholar 

  13. MacDonald RG, Pfeffer S, Coussens L, Tepper M, Brocklebank C, Mole J, et al. (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science 239: 1134–1137.

    Article  PubMed  CAS  Google Scholar 

  14. Nishimoto, I (1993) The IGF-II receptor system a G-protein-linked mechanism. Mol Reprod Dev 35: 398–407.

    Article  PubMed  CAS  Google Scholar 

  15. Okamoto T, Katada T, Murayama Y, Ui M, Ogata, E, Nishimoto, I (1990) A simple structure encodes G protein-activating function of the IGF-II/mannose-6-phosphate receptor. Cell 62: 709–717.

    Article  PubMed  CAS  Google Scholar 

  16. Blanchard M, Barenton B, Sullivan A, Foster B, Guyda, H, Posner, B (1988) Characterisation of the insulin-like growth factor (IGF) receptor in K562 erythroleukemia cells; evidence for a biological function for the type II IGF receptor. Mol Cell Endocrinol 56: 235–244.

    Article  PubMed  CAS  Google Scholar 

  17. Mathieu M, Rochefort H, Barenton B, Prebois, C, Vignon, F (1990) Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity ofIGF-II. Mol Endocrinol 4: 1327–1335.

    Article  PubMed  CAS  Google Scholar 

  18. Korner C, Nurnberg B, Uhde, M, Braulke, T (1995) Mannose-6-phosphate/insulin-like growth factor II receptor fails to interact with G-proteins. J Biol Chem 270: 287–295.

    Article  PubMed  CAS  Google Scholar 

  19. Rubin R, Baserga R (1995) Insulin-like growth factor-I receptor. Its role in cell proliferation, apotosis and tumorigenicity. Lab Invest 73: 311–331.

    Google Scholar 

  20. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, et al. (1994) Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604–3612.

    PubMed  CAS  Google Scholar 

  21. Coppola D, Ferber A, Miura M, Sell C, D’Ambrosio C, Rubin, R, et al. (1994) A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activites of the epidermal growth factor receptor. Mol Cell Biol 14: 4588–4595.

    PubMed  CAS  Google Scholar 

  22. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis, A (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 IGF receptor. Proc Natl Acad Sci USA 90: 11217–112121.

    Google Scholar 

  23. Baserga R (1994) Oncogenes and the strategy of growth factors. Cell 79: 927 930.

    Google Scholar 

  24. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Philips PD, et al. (1992) Constitutive overexpression of insulin-like growth factor 1 and inslin-like growth facotr 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 3: 195–205.

    Google Scholar 

  25. Sell C, Baserga, R, Rubin, R (1995) Insulin-like growth factor I ( IGF-I) and the IGF-I receptor prevent etoposide-induced apotosis. Cancer Res 55: 303–306.

    Google Scholar 

  26. Miura M, Surmacz E, Burgaud J, Baserga, R (1995) Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem 270: 22639–22644.

    Article  PubMed  CAS  Google Scholar 

  27. Jones JI, Gockerman A, Busby WH, Wright G, Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the a5ß1 integrins by means of its Arg-GlyAsp sequence. Proc Natl Acad Sci USA 90: 10553–10557.

    Article  PubMed  CAS  Google Scholar 

  28. De Mellow JS, Baxter RC (1988) Growth hormone-dependent insulin-like growth factor ( IGF) binding protein both inhibits and potentiates IGF-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156: 199–204.

    Google Scholar 

  29. Cohen P, Lamson G, Okahima, T, Rosenfeld RG (1993) Transfection of the insulin-like growth factor binding protein-3 gene into Balb/C fibroblasts inhibits cellular growth. Mol Endocrinol 7: 380–386.

    Article  PubMed  CAS  Google Scholar 

  30. Chen, J.-C., Shao Z-M, Sheikh, M (1994) Insulin-like growth factor binding protein enhancement of insulin-like growth factor-I ( IGF-I) mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158: 69–78.

    Google Scholar 

  31. Pratt SE, Pollack MN (1994) Insulin-like growth factor binding protein 3 (IGFBP-3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 198: 292–297.

    Article  PubMed  CAS  Google Scholar 

  32. Oh Y, Muller HL, Lee D, Fielder P, Rosenfeld RG (1993) Characterisation of the affinities of insulin-like growth factor (IGF)-binding proteins 1–4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132: 1337–1344.

    Google Scholar 

  33. Oh Y, Muller HL, Pham H, Rosenfeld RG (1993) Demonstration of receptors for insulin-like growth factor binding protein-3 on HS578T human breast cancer cells. J Biol Chem 268: 26045–26048.

    PubMed  CAS  Google Scholar 

  34. Valentinis B, Bhala A, De Angelis T, Baserg, R, Cohen P (1995) The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9: 361–367.

    Article  PubMed  CAS  Google Scholar 

  35. McGuire Jr, W, Jackson JG, Figueroa JA, Shimasaki SA, Powell DR, Yee D (1992) Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP1 as an inhibitor of insulin-like growth factor action. Natl Cancer Inst 84: 1336–13411.

    Article  CAS  Google Scholar 

  36. Jones JI, D’Ercole AJ, Camacho-Hubner C, Clemmons DR (1991) Phosphorylation of insulin-like growth factor binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 88: 7481–7485.

    Article  PubMed  CAS  Google Scholar 

  37. Lewis AA, Gomez ET, Turner CW (1942) Mammary gland development with mammogen I in the castrated and the hypophysectomized rat. Endocrinology 30: 37–47.

    Article  Google Scholar 

  38. Lyons WR (1993) Hormonal synergism in mammary growth. Proc R Soc 149: 303–325.

    Google Scholar 

  39. Ruan W, Newman CB, Kleinberg DL (1992) Intact and aminoterminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Nat! Acad Sci USA 89: 10872–10876.

    Article  CAS  Google Scholar 

  40. Schlechter NL, Russell SM, Spencer EM, Nicoll CS (1986) Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci USA 83: 7932–7934.

    Article  PubMed  CAS  Google Scholar 

  41. Murphy LJ, Bell GI, Friesen HG (1987) Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology 120: 1279–1282.

    Article  PubMed  CAS  Google Scholar 

  42. Ruan W, Catanese R, Wieczorek R, Feldman M, Kleinberg DL (1995) Estradiol enhances the stimulatory effect of insulin-like growth factor-I ( IGF-I) on mammary development and growth-hormoneinduced IGF-I messenger ribonucleic acid. Endocrinology 136: 1296–1302.

    Google Scholar 

  43. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996) Targetted expression of des (1–3) human insulin-like growth factor I (IGF-I) in transgenic mice influences mammary galnd development and IGF-binding protein expression. Endocrinology, in press.

    Google Scholar 

  44. Neuenschwander S, Schwartz A, Wood TL, Roberts CTJ (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97: 2225–2232.

    Article  PubMed  CAS  Google Scholar 

  45. Myal Y, Shiu RPC, Bhaumick B, M, B (1984) Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T47D) in culture. Cancer Res 44: 5486–5490.

    PubMed  CAS  Google Scholar 

  46. Karey K, Sirbasku, D (1988) Differential responsiveness of human breast cancer cell lines to growth factors and l713-estradiol. Cancer Res 48: 4083–4092.

    PubMed  CAS  Google Scholar 

  47. Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A, et al. (1988) Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48: 6691–6696.

    PubMed  CAS  Google Scholar 

  48. Cullen K, Yee D, Sly W, Perdue J, Hampton B, Lippman M, et al. (1990) Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48–53.

    PubMed  CAS  Google Scholar 

  49. Ahmed SR, Manni A, Gray G. Hammond JM (1990) Characterisation and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. AntiCancer Res 10: 1217–1223.

    CAS  Google Scholar 

  50. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB (1986) Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46: 4613–4619.

    PubMed  CAS  Google Scholar 

  51. Minuto F, Delmonte P, Barreca A, Nicolin A, Giordano G (1987) Partial characterisation of somatomedin C-like immunoreactivity secreted by breast cancer cells in vitro. Mol Cell Endocrinol 54: 179–184.

    Article  PubMed  CAS  Google Scholar 

  52. Osborne CK, Coronado EB, Kitten LJ, Arteaga CR, Fuqua SAW, Ramasharma K, et al. (1989) Insulin-like growth factor-II ( IGF-II ): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3: 1701–1709.

    Google Scholar 

  53. Lee AV, Darbre P, King RJB (1994) Processing of insulin-like growth factor-II ( IGF-II) by human breast cancer cells. Mol Cell Endocrinol 99: 211–220.

    Google Scholar 

  54. Daly R, Harris W, Wang D, Darbre P (1991) Autocrine production of insulin like growth factor-II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ 2: 457–464.

    PubMed  CAS  Google Scholar 

  55. Cullen K, Lippman M, Chow D, Hill S, Rosen N, Zwiebel, J (1992) Insulin-like growth factor-II over expression in MCF-7 cells induces phenotypic chances associated with malignant progression. Mol Endocrinol 6: 91–100.

    Article  PubMed  CAS  Google Scholar 

  56. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF (1995) Mammary cancer in transgenic mice overexpressing insulin-like growth factor II ( IGF-II ). Br J Cancer 72: 1189–1193.

    Google Scholar 

  57. Yee D, Paik S, Levovic GS, Marcus RR, Favoni RE, Cullen KJ, et al. (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509–517.

    Article  PubMed  CAS  Google Scholar 

  58. Paik, S (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22: 31–38.

    Article  PubMed  CAS  Google Scholar 

  59. Toropainen EM, Lipponen PK, Syrjanen KJ (1995) Expression of insulin-like growth factor II in human breast cancer as related to established prognostic factors and long-term prognosis. AntiCancer Res 15: 2669–2674.

    PubMed  CAS  Google Scholar 

  60. Giani C, Cullen KJ, Campani D, Rasmussen A (1996) IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 41: 43–50.

    Article  PubMed  CAS  Google Scholar 

  61. Singer C, Smith HS, Lippman ME, Cullen KJ (1992) IGF-I and IGF-II expression in fibroblasts derived from tumor, normal breast, and skin of breast cancer patients. Proc AACR 33, A1612.

    Google Scholar 

  62. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch T, Cullen KJ (1995) Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55: 2448–2454.

    PubMed  CAS  Google Scholar 

  63. Peyrat JP, Bonneterre J, Hecquet B, Vermin P, Louchez MM, Fournier C, et al. (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29: 492–497.

    Article  Google Scholar 

  64. Pollack MN, Huynh HT, Lefebvre SP (1992) Tamoxifen reduces serum insulin-like growth factor I ( IGF-I ). Breast Cancer Res Treat 22: 91–100.

    Google Scholar 

  65. Lahti EI, Knip M, Laatikainen TJ (1994) Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long-term tamoxifen. Cancer 74: 618–624.

    Article  PubMed  CAS  Google Scholar 

  66. Lien EA, Johannessen DC, Aakvaag A, Lonning PE (1992) Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 41: 541–543.

    Article  PubMed  CAS  Google Scholar 

  67. Lonning PE, Hall K, Aakvaag A, Lien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein 1 in breast cancer patients. Cancer Res 52: 4719–4723.

    PubMed  CAS  Google Scholar 

  68. Reed MJ, Christodoulides A, Koistinen R, Seppala M, Teale JD, Ghilchik MW (1992) The effect of endocrine therapy with methoxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer 52: 208–212.

    Article  PubMed  CAS  Google Scholar 

  69. Malaab SA, Pollack MN, Goodyer CG (1992) Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A, 788–793.

    Article  Google Scholar 

  70. Huynh HT, Tetenes E, Wallace L, Pollack M (1993) In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53:1727–1730.

    Google Scholar 

  71. Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, et al. (1995) Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. group. Italian Trials in Medical Oncology. Breast Cancer Res Treat 34: 237–244.

    Google Scholar 

  72. Canobbio L, Cannata D, Miglietta L, Boccardo F (1995) Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients; clinical activity and effect on insulin-like growth factor-I ( IGF-I) levels. AntiCancer Res 15: 2687–2690.

    Google Scholar 

  73. Daws MR, Westley BR, May FE (1996) Paradoxical effects of overexpression of the type I insulin-like growth factor ( IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. Endocrinology 137: 1177–1186.

    Google Scholar 

  74. Guvakova MA, Surmacz, E (1997) Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231: 149–162.

    Article  PubMed  CAS  Google Scholar 

  75. Peyrat J-P, Bonneterre J, Beuscart J, Dijane J, Demaille A (1988) Insulin-like growth factor I receptors in human breast cancer and their relationship to estradiol and progesterone receptors. Cancer Res 48: 6429–6433.

    PubMed  CAS  Google Scholar 

  76. Pekonen F, Partanen S, Makinen T, Rutanen EM (1988) Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343–1347.

    PubMed  CAS  Google Scholar 

  77. Foekens JA, Portengen H, Jansen M, Klun G (1989) Insulin-like growth factor-I receptors and insulin-like growth factor-I-like activity in human primary breast cancer. Cancer (Phila) 63: 2139–2147.

    Article  CAS  Google Scholar 

  78. Berns EMJJ, Klijn JGM, van Staveren IL, Portegen, H, Foekens JA (1990) Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52: 1036–1039.

    Google Scholar 

  79. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, et al. (1996) M6P/IGF2 receptor: a candidate breast tumor supressor gene. Oncogene 12: 2003–2009.

    PubMed  CAS  Google Scholar 

  80. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast cancer cell lines: correlation with estrogen receptor status. Endocrinology 127: 2679–2686.

    Article  PubMed  CAS  Google Scholar 

  81. Yee D, Favoni R, Lippman M, Powell D (1991) Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18: 3–10.

    Article  PubMed  CAS  Google Scholar 

  82. Fontana JA, Clemmons DR, LeRoith, D (1991) Retinoid modulation of insulin-like growth factor binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 128: 1115–1122.

    Article  PubMed  CAS  Google Scholar 

  83. Huynh H, Yang XF, Pollak, M (1996) A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7: 1501–1506.

    PubMed  CAS  Google Scholar 

  84. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee, D (1993) Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52: 196–205.

    Article  PubMed  CAS  Google Scholar 

  85. Shao, Z.-M., Sheikh MS, Ordonez JV, Feng P, Kute T, Chen J-C, et al. (1992) IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma. Cancer Res 52: 5100–5103.

    PubMed  CAS  Google Scholar 

  86. Yee D, Sharma J, Hilsenbeck SG (1994) Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. Natl Cancer Inst 86: 1785–1789.

    Article  CAS  Google Scholar 

  87. Rocha R, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee, D (1995) Insulin-like growth factor binding protein-3 (BP3) mRNA and protein expression are correlated in primary breast cancer tissue; higher levels are detected in tumors with poor prognostic features. Natl Cancer Inst 88: 601–606.

    Article  Google Scholar 

  88. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C-N, Lee AV, et al. (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3: 103–109.

    PubMed  CAS  Google Scholar 

  89. Nolan M, Jankowski L, Prisco M, Xu S, Guvakova M, Surmacz E (1997) Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer, in press.

    Google Scholar 

  90. Surmacz, E, Burgard J-L (1995) Overexpression of IRS-1 in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1: 1429–1436.

    PubMed  CAS  Google Scholar 

  91. Early Breast Cancer Trialists Collaborative Group. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15: 71–85.

    Google Scholar 

  92. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167–1177.

    Article  PubMed  CAS  Google Scholar 

  93. Westley BR, May FEB (1994) Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol 51: 1–9.

    Article  PubMed  CAS  Google Scholar 

  94. Stewart A, Westley B, May F (1992) Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 66: 640–648.

    Article  PubMed  CAS  Google Scholar 

  95. Mathieu M, Vignon F, Capony, F, Rochefort H (1991) Estradiol down regulates the mannose-6phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Cell Endocrinol 5: 815–822.

    Article  CAS  Google Scholar 

  96. Arteaga CL, Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49: 6237–6241.

    PubMed  CAS  Google Scholar 

  97. Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstradiatis A, et al. (1997) Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 94: 3777–3782.

    Article  PubMed  CAS  Google Scholar 

  98. Vignon F, Bouton M-M, Rochefort H (1988) Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146: 1502–1508.

    Article  Google Scholar 

  99. Hasmann M, Rattel B, Loser R (1994) Preclinical data for droloxifene. Cancer Lett 84: 101–116.

    Article  PubMed  CAS  Google Scholar 

  100. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla G (1994) The unliganded estrogen receptor ( ER) transduces growth factor signals. J Steroid Biochem Mol Biol 48: 481–486.

    Google Scholar 

  101. Lee AV, Weng C-N, Jackson JG, Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152: 39–47.

    Article  PubMed  CAS  Google Scholar 

  102. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D (1993) Recombinant insulin-like growth factor binding protein 1 inhibits IGF-I, serum and estrogen dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157: 229–236.

    Article  PubMed  CAS  Google Scholar 

  103. Huynh H, Yang X, Pollak M (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016–1021.

    Article  PubMed  CAS  Google Scholar 

  104. Freiss G, Rochefort H, Vignon F (1990) Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun 3: 919–926.

    Article  Google Scholar 

  105. Guvakova M, Surmacz E (1997) Tamoxifen interferes with the insulin-like growth factor I receptor ( IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57: 2606–2610.

    Google Scholar 

  106. Freiss G, Vignon F (1994) Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 8: 1389–1396.

    Article  PubMed  CAS  Google Scholar 

  107. Cho H, Aronica S, Katzenellenbogen BS (1994) Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3’-5’-monophosphate, estradiol, insulin-like growth factor-I and serum factors. Endocrinology 134: 658–664.

    Article  PubMed  CAS  Google Scholar 

  108. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS (1996) Peptide growth factors cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137: 1735–1744.

    Article  PubMed  CAS  Google Scholar 

  109. Patrone C, Ma ZQ, Pollio G, Agrati P, Parker MG, Maggi A (1996) Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells. Mol Endocrinol 10: 499–507.

    Article  PubMed  CAS  Google Scholar 

  110. Lee AV, Toi M, Yee D (1994) Tamoxifen resistant MCF-7 cells exhibit increased expression of insulin-like growth factor-II. Breast Cancer Res Treat 32S, 57.

    Article  Google Scholar 

  111. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR (1993) Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A, 2256–2264.

    Article  Google Scholar 

  112. McCotter D, van den Berg HW, Boylan M, McKibben B (1996) Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett 99: 239–245.

    Article  PubMed  CAS  Google Scholar 

  113. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP (1996) Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in human breast cancer. Br J Cancer 74: 1242–1247.

    Article  PubMed  CAS  Google Scholar 

  114. Barni S, Lissoni P, Brivio F, Fumugalli, Merlini D, Cataldo M, Rovelli, F, et al. (1994) Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 80: 212–215.

    PubMed  CAS  Google Scholar 

  115. Bhatavedar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, et al. (1994) Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 30: 293–297.

    Article  Google Scholar 

  116. Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50: 6931–6935.

    PubMed  CAS  Google Scholar 

  117. Papa V, Gliozzo B, Clark G, McGuire W, Moore D, Fujita-Yamaguchi Y, et al. (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736–3740.

    PubMed  CAS  Google Scholar 

  118. Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID (1991) Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II. Mol Endocrinol 5: 709–717.

    Article  PubMed  CAS  Google Scholar 

  119. McGuire WL (1988) Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 6: 1071–1072.

    PubMed  CAS  Google Scholar 

  120. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079–3083.

    PubMed  CAS  Google Scholar 

  121. Arteaga CL, Kitten L, Coronado E, Jacobs S, Kull F, Allred DC, et al. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin. Invest 84: 1418–1423.

    Google Scholar 

  122. Brünner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen KJ (1993) Effect of endocrine therapy on growth of T61 human beast cancer xenografts is directly correlated to a specific downregulaton of insulin-like growth factor II ( IGF-II ). Eur J Cancer 29A, 562–569.

    Google Scholar 

  123. Yee D, Jackson JG, Kozelsky TW, Figueroa JA (1994) Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 cells. Cell Growth Differ 5: 73–77.

    PubMed  CAS  Google Scholar 

  124. Huynh H, Beamer M, Pollack M (1997) Over-expression of insulin-like growth factor binding protein 4 in MCF-7 breast cancer cells is associated with reduced responsivity to insulin-like growth factors in vitro and reduced tumor growth in vivo. Proc Am Assoc Cancer Res 38, A3954.

    Google Scholar 

  125. Van Den Berg C, Cox GN, Stroh CA, Hilsenbeck SG, Weng C-N, McDermott MJ, et al. (1997) Polyethylene glycol conjugated insulin-like growth factor binding protein-I (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33: 1108–1113.

    Article  PubMed  Google Scholar 

  126. Baserga, R (1996) Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 14: 150–152.

    Article  PubMed  CAS  Google Scholar 

  127. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, et al. (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218–2222.

    PubMed  CAS  Google Scholar 

  128. Neuenschwander S, Roberts CT, Leroith D (1995) Growth inhibition of human breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136: 4298–4303.

    Article  PubMed  CAS  Google Scholar 

  129. Lee AV, Yee D (1997) The IGF system as prognostic markers in breast cancer. Breast Cancer Res Treat 47: 295–302.

    Article  Google Scholar 

Download references

Authors
  1. A. V. Lee PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Yee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. College of Medicine, The Pennsylvania State University, Hershey, PA, USA

    Andrea Manni MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lee, A.V., Yee, D. (1999). Role of the IGF System in Breast Cancer Proliferation and Progression. In: Manni, A. (eds) Endocrinology of Breast Cancer. Contemporary Endocrinology, vol 11. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-699-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-699-7_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5139-0

  • Online ISBN: 978-1-59259-699-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation